ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C

ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C - ITPA SNP and sofosbuvir plus RBV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023086

Enrollment

500

Registered

2016-07-08

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: genotype 2 HCV-infected patients

Exclusion criteria

Exclusion criteria: Patients with decompensated cirrhosis

Design outcomes

Primary

Measure	Time frame
sustained virological response (negative for serum HCV RNA at 24 weeks after the treatment)	—

Secondary

Measure	Time frame
Hemoglobin during the treatment period	—

Countries

Japan

Contacts

Public ContactMichio Imamura

Applied Life Science, Institute of Biomedical & Health Science, Hir oshima University Department of Gastroenterology a nd Metabolism

mimamura@hiroshima-u.ac.jp082-257-5190

Outcome results